Exclusive Sales and Commercialization Agreement with Imocog
Cumulative 2,400 Prescriptions Since Initial Launch

Daewoong Pharmaceutical announced on September 22 that it signed an exclusive domestic sales and commercialization agreement with digital healthcare company Imocog for Cogthera, a digital therapeutic device for mild cognitive impairment, and Cogscreen, an early cognitive function screening solution.


This is the first time that Daewoong Pharmaceutical is introducing a digital therapeutic (DTx) device. The company plans to expand a cognitive health management system in clinical settings, encompassing early cognitive function screening with Cogscreen, diagnosis and prescription by medical professionals, and digital therapy with Cogthera.


Lee Chang-jae, CEO of Daewoong Pharmaceutical (left), and Roh Youheon, CEO of Imocog, are posing for a commemorative photo after signing an exclusive domestic sales and commercialization agreement for Korea's first digital therapeutic device for mild cognitive impairment, 'Cogthera,' and the digital cognitive function early screening solution, 'CogScreen.' Daewoong Pharmaceutical

Lee Chang-jae, CEO of Daewoong Pharmaceutical (left), and Roh Youheon, CEO of Imocog, are posing for a commemorative photo after signing an exclusive domestic sales and commercialization agreement for Korea's first digital therapeutic device for mild cognitive impairment, 'Cogthera,' and the digital cognitive function early screening solution, 'CogScreen.' Daewoong Pharmaceutical

View original image

Cogthera is a digital therapeutic device in which patients, upon a doctor’s prescription, perform cognitive intervention training twice daily for 12 weeks using a mobile app. It received approval from the Ministry of Food and Drug Safety in May 2025 and is the first digital therapeutic device in Korea indicated for mild cognitive impairment. It has been designated as Innovative Medical Device No. 35.


From its initial prescription in October 2025 to the end of August this year, the cumulative number of prescriptions reached 2,400. Among elderly patients with an average age of 73, the rate of training initiation after prescription was 99.3%. In May this year, it was temporarily listed as a non-reimbursed item under the national health insurance.


Cogscreen is a solution that screens for cognitive function in about five minutes through a web link, without requiring a separate app installation. Rather than diagnosing dementia, it identifies the possibility of cognitive impairment, assisting healthcare professionals with further evaluation and treatment decisions.


Daewoong Pharmaceutical is responsible for sales, marketing, and commercialization of Cogthera and Cogscreen to domestic hospitals, clinics, and public agencies, including government and public health centers. Imocog handles product supply and quality control, technical support, and the operation of patient support programs. Through this agreement, Daewoong Pharmaceutical plans to expand its digital healthcare business to include prescription-based digital treatments in the central nervous system (CNS) field.



Lee Chang-jae, CEO of Daewoong Pharmaceutical, stated, “This agreement marks Daewoong Pharmaceutical’s first introduction of a digital therapeutic device,” adding, “We will work to expand the management system that connects early cognitive screening and prescription-based treatments within clinical settings.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing